High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.
10.4048/jbc.2016.19.2.156
- Author:
Eun Young KIM
1
;
Sung Im DO
;
Keehoon HYUN
;
Yong Lai PARK
;
Dong Hoon KIM
;
Seoung Wan CHAE
;
Jin Hee SOHN
;
Chan Heun PARK
Author Information
1. Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. chanheun1@gmail.com
- Publication Type:Original Article
- Keywords:
Breast neoplasms;
Plasminogen activator inhibitor 1;
Urokinase-type plasminogen activator
- MeSH:
Breast Neoplasms;
Breast*;
Carcinoma, Ductal*;
Carcinoma, Intraductal, Noninfiltrating;
Diagnosis;
Estrogens;
Hormone Replacement Therapy;
Humans;
Lymph Nodes*;
Neoplasm Metastasis*;
Plasminogen Activator Inhibitor 1;
Prognosis;
Skin;
Thoracic Wall;
Urokinase-Type Plasminogen Activator*
- From:Journal of Breast Cancer
2016;19(2):156-162
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: In the present study, we evaluated the levels of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) by performing immunohistochemical staining to determine whether they were reliable prognostic markers in patients with breast cancer. METHODS: Demographic and clinicopathological parameters of 214 patients with invasive ductal carcinoma (IDC) and 80 patients with ductal carcinoma in situ (DCIS) who were diagnosed and treated from 2006 to 2010 were analyzed. Tissue microarray was constructed and immunohistochemical staining was performed for each specimen. RESULTS: Univariate analyses showed that age at diagnosis, history of hormone replacement therapy, radiation therapy, skin and chest wall invasion, Paget disease, lymphovascular invasion, estrogen receptor positivity, and triple-negative subtype were significantly associated with patient prognosis (p<0.005). Patients with DCIS showed higher PAI-1 expression than patients with IDC (82.5% and 36.2%, respectively; p=0.012). Lymph node metastasis was more frequent in patients with high uPA levels than in patients with low uPA levels (p=0.001). CONCLUSION: Our results suggested that PAI-1 was involved in tumor progression in the early stages of breast cancer, such as DCIS. In addition, our results suggested that high uPA levels were associated with the lymph node metastasis of IDC.
